C. H. F. Hansen

Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments

This study develops modified fecal virome transplants (FVT) to reduce donor variability and infection risks in treating C. difficile infections, showing improved efficacy and safety in a mouse model.

Transfer of modified fecal viromes improve blood glucose regulation and alleviates symptoms of metabolic dysfunction-associated fatty liver disease in an obesity male mouse model

Modified fecal virome transplantation improves blood glucose regulation in obese mice without reducing weight gain, while unmodified FVT reduces immune cell proportions in adipose tissue.